HLB Co. Ltd (028300) - Total Assets

Latest as of September 2025: ₩703.48 Billion KRW ≈ $476.74 Million USD

Based on the latest financial reports, HLB Co. Ltd (028300) holds total assets worth ₩703.48 Billion KRW (≈ $476.74 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of HLB Co. Ltd for net asset value and shareholders' equity analysis.

HLB Co. Ltd - Total Assets Trend (2005–2024)

This chart illustrates how HLB Co. Ltd's total assets have evolved over time, based on quarterly financial data.

HLB Co. Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

HLB Co. Ltd's total assets of ₩703.48 Billion consist of 19.4% current assets and 80.6% non-current assets.

Asset Category Amount (KRW) % of Total Assets
Cash & Equivalents ₩93.05 Billion 10.5%
Accounts Receivable ₩9.01 Billion 1.0%
Inventory ₩9.69 Billion 1.1%
Property, Plant & Equipment ₩83.77 Billion 9.4%
Intangible Assets ₩272.79 Billion 30.7%
Goodwill ₩39.64 Billion 4.5%

Asset Composition Trend (2005–2024)

This chart illustrates how HLB Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see HLB Co. Ltd market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: HLB Co. Ltd's current assets represent 19.4% of total assets in 2024, an increase from 0.0% in 2005.
  • Cash Position: Cash and equivalents constituted 10.5% of total assets in 2024, down from 17.3% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 34.0% of total assets, an increase from 0.0% in 2005.
  • Asset Diversification: The largest asset category is intangible assets at 30.7% of total assets.

HLB Co. Ltd Competitors by Total Assets

Key competitors of HLB Co. Ltd based on total assets are shown below.

Company Country Total Assets
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $7.59 Billion
Summit Therapeutics PLC
NASDAQ:SMMT
USA $261.73 Million
Argen-X
F:1AE
Germany €7.18 Billion
Metsera, Inc. Common Stock
NASDAQ:MTSR
USA $639.66 Million
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
China CN¥3.06 Billion
R&G PharmaStudies Co. Ltd. A
SHE:301333
China CN¥2.31 Billion
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
China CN¥819.45 Million
Innovita Biological Technology Co. Ltd. A
SHG:688253
China CN¥2.16 Billion

HLB Co. Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.65 1.18 2.57
Quick Ratio 0.57 1.06 2.52
Cash Ratio 0.00 0.58 0.00
Working Capital ₩-63.67 Billion ₩26.95 Billion ₩153.55 Billion

HLB Co. Ltd - Advanced Valuation Insights

This section examines the relationship between HLB Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 17.04
Latest Market Cap to Assets Ratio 0.01
Asset Growth Rate (YoY) 18.1%
Total Assets ₩887.42 Billion
Market Capitalization $5.41 Billion USD

Valuation Analysis

Below Book Valuation: The market values HLB Co. Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: HLB Co. Ltd's assets grew by 18.1% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for HLB Co. Ltd (2005–2024)

The table below shows the annual total assets of HLB Co. Ltd from 2005 to 2024.

Year Total Assets Change
2024-12-31 ₩887.42 Billion
≈ $601.40 Million
+18.05%
2023-12-31 ₩751.72 Billion
≈ $509.43 Million
-22.28%
2022-12-31 ₩967.27 Billion
≈ $655.50 Million
+30.06%
2021-12-31 ₩743.69 Billion
≈ $503.99 Million
+5.27%
2020-12-31 ₩706.48 Billion
≈ $478.77 Million
+94.83%
2019-12-31 ₩362.61 Billion
≈ $245.74 Million
+19.26%
2018-12-31 ₩304.04 Billion
≈ $206.04 Million
+61.56%
2017-12-31 ₩188.19 Billion
≈ $127.54 Million
+0.80%
2016-12-31 ₩186.71 Billion
≈ $126.53 Million
+0.83%
2015-12-31 ₩185.17 Billion
≈ $125.49 Million
+241.32%
2014-12-31 ₩54.25 Billion
≈ $36.77 Million
+50.27%
2013-12-31 ₩36.10 Billion
≈ $24.47 Million
-5.60%
2012-12-31 ₩38.24 Billion
≈ $25.92 Million
-29.51%
2011-12-31 ₩54.25 Billion
≈ $36.76 Million
-6.64%
2010-12-31 ₩58.11 Billion
≈ $39.38 Million
-28.68%
2009-12-31 ₩81.48 Billion
≈ $55.22 Million
+16.90%
2008-12-31 ₩69.70 Billion
≈ $47.23 Million
+45.04%
2007-12-31 ₩48.05 Billion
≈ $32.56 Million
+48.89%
2006-12-31 ₩32.27 Billion
≈ $21.87 Million
+30.35%
2005-12-31 ₩24.76 Billion
≈ $16.78 Million
--

About HLB Co. Ltd

KQ:028300 Korea Biotechnology
Market Cap
$5.41 Billion
₩7.98 Trillion KRW
Market Cap Rank
#3396 Global
#86 in Korea
Share Price
₩60800.00
Change (1 day)
-3.49%
52-Week Range
₩37000.00 - ₩68200.00
All Time High
₩120800.00
About

HLB Co., Ltd. manufactures and constructs lifeboats and glass fiber pipes in South Korea and internationally. It engages in the repair and inspection of lifeboats; fabrication and installation of pipes; development and manufacturing of biopharmaceuticals products, such as anti-cancer drugs; and manufacture and sale of medical devices, as well as manufacture and sale of quasi-drugs products, inclu… Read more